The inverse correlation between high YY1 and low RKIP expressions has been observed across various malignancies (such as prostate cancer, melanoma, colorectal cancer, cervical cancer, hematologic malignancies, etc.), suggesting a tightly regulated molecular axis influencing tumor progression and therapeutic response. Here, YY1 is linked to prostate carcinoma.